

Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	8	6.9	116.2	(50.0-229.0)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.3	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	5	1.7	295.9	(95.4-690.6)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	23.9	50.2	(25.9-87.7)
Female	1	0.2	nc	(nc-nc)	Female	24	22.2	108.0	(69.2-160.7)
<u>Lung and Bronchus</u>									
Male	2	3.1	nc	(nc-nc)					
Female	2	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	6.2	144.9	(66.1-275.1)	Male	4	4.5	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	1	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.5	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	34	29.1	117.0	(81.0-163.5)	Female	3	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	9	7.5	119.2	(54.4-226.4)	<u>Ovary</u>				
Female	7	6.8	102.4	(41.0-211.1)	Female	1	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.8	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	25	25.5	98.2	(63.5-145.0)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.6	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.1	nc	(nc-nc)
Male	3	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	6	6.2	96.4	(35.2-209.9)
Male	5	2.8	181.4	(58.4-423.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.9	nc	(nc-nc)	Female	9	6.4	139.9	(63.8-265.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.4	nc	(nc-nc)	Male	89	92.3	96.4	(77.4-118.6)
Female	0	0.7	nc	(nc-nc)	Female	84	92.1	91.2	(72.8-113.0)
<u>Lung and Bronchus</u>									
Male	10	11.6	86.1	(41.2-158.4)					
Female	10	11.7	85.5	(40.9-157.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	38.8	92.7	(64.9-128.3)	Male	26	25.7	101.1	(66.0-148.1)
Female	11	15.9	69.4	(34.6-124.2)	Female	25	23.6	106.1	(68.6-156.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	7.7	117.6	(53.6-223.2)	Male	4	7.4	nc	(nc-nc)
Female	5	7.2	69.4	(22.4-161.9)	Female	7	6.8	103.5	(41.5-213.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.2	nc	(nc-nc)	Male	36	22.8	158.2	(110.8-219.0)
Female	192	172.7	111.2	(96.0-128.1)	Female	21	21.4	98.1	(60.7-149.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	6.3	nc	(nc-nc)	Male	16	18.1	88.3	(50.5-143.5)
<u>Colon / Rectum</u>					Female	14	8.9	156.9	(85.7-263.3)
Male	49	43.2	113.3	(83.8-149.8)	<u>Ovary</u>				
Female	47	48.6	96.7	(71.1-128.6)	Female	12	16.0	75.0	(38.7-131.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	18	10.4	172.5	(102.2-272.7)	Male	10	13.3	75.4	(36.1-138.7)
Female	4	3.0	nc	(nc-nc)	Female	20	15.5	129.3	(78.9-199.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.6	140.3	(45.2-327.5)	Male	162	139.1	116.4	(99.2-135.8)
Female	8	3.4	238.2	(102.6-469.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	9.1	175.4	(100.2-284.9)
Male	31	21.4	145.0	(98.5-205.8)	Female	3	6.1	nc	(nc-nc)
Female	17	13.8	123.5	(71.9-197.8)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.4	94.2	(34.4-205.1)
Male	7	5.8	121.4	(48.6-250.2)	<u>Thyroid</u>				
Female	4	2.1	nc	(nc-nc)	Male	13	10.3	126.1	(67.1-215.6)
<u>Leukemia</u>					Female	36	34.4	104.6	(73.2-144.8)
Male	18	15.8	113.6	(67.3-179.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	12.9	116.1	(64.9-191.4)	Female	44	39.5	111.4	(80.9-149.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	13.3	135.4	(80.2-214.0)	Male	602	523.8	114.9	(105.9-124.5)
Female	4	4.8	nc	(nc-nc)	Female	631	591.4	106.7	(98.5-115.3)
<u>Lung and Bronchus</u>									
Male	72	70.2	102.6	(80.3-129.2)					
Female	93	81.6	114.0	(92.0-139.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	9.5	136.4	(72.6-233.3)	Male	12	6.4	188.3	(97.2-328.9)
Female	3	3.4	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.8	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	5.6	89.7	(28.9-209.4)
Female	45	40.1	112.2	(81.8-150.1)	Female	11	4.7	232.9	(116.1-416.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	11	4.8	231.5	(115.4-414.3)
<u>Colon / Rectum</u>					Female	0	2.0	nc	(nc-nc)
Male	18	10.8	167.1	(99.0-264.0)	<u>Ovary</u>				
Female	15	10.3	145.6	(81.4-240.1)	Female	8	3.6	221.0	(95.2-435.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.7	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	33	37.7	87.4	(60.2-122.8)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.3	nc	(nc-nc)
Male	11	5.5	199.1	(99.2-356.2)	Female	1	1.3	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.1	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	2	7.2	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.7	nc	(nc-nc)	Female	11	9.4	116.6	(58.1-208.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.5	nc	(nc-nc)	Male	147	133.2	110.4	(93.2-129.7)
Female	1	1.1	nc	(nc-nc)	Female	158	132.2	119.5	(101.6-139.7)
<u>Lung and Bronchus</u>									
Male	20	17.9	112.0	(68.4-173.0)					
Female	28	18.7	149.4	(99.3-216.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	4.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.6	nc	(nc-nc)	Male	14	22.5	62.1	(33.9-104.2)
Female	1	0.1	nc	(nc-nc)	Female	9	14.5	62.2	(28.4-118.1)
<u>Lung and Bronchus</u>									
Male	3	3.2	nc	(nc-nc)					
Female	3	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	24.3	127.4	(86.6-180.9)	Male	26	15.8	164.5	(107.4-241.0)
Female	7	8.9	79.0	(31.7-162.9)	Female	22	12.4	176.9	(110.8-267.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	4.5	200.3	(91.4-380.3)	Male	3	4.7	nc	(nc-nc)
Female	5	3.9	129.0	(41.6-301.0)	Female	1	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	18	13.9	129.6	(76.7-204.8)
Female	105	99.4	105.7	(86.4-127.9)	Female	16	12.0	133.7	(76.4-217.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.3	nc	(nc-nc)	Male	11	11.6	95.0	(47.3-169.9)
<u>Colon / Rectum</u>					Female	6	5.0	118.9	(43.4-258.7)
Male	21	27.0	77.7	(48.1-118.8)	<u>Ovary</u>				
Female	25	26.9	93.0	(60.2-137.3)	Female	8	9.0	88.8	(38.2-175.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.7	74.1	(23.9-173.0)	Male	12	8.4	142.6	(73.6-249.1)
Female	2	1.7	nc	(nc-nc)	Female	9	8.6	104.7	(47.8-198.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.7	nc	(nc-nc)	Male	111	92.4	120.1	(98.8-144.6)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	5.7	122.1	(48.9-251.6)
Male	10	13.5	74.1	(35.5-136.3)	Female	4	3.4	nc	(nc-nc)
Female	4	7.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.6	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
<u>Leukemia</u>					Female	11	17.4	63.3	(31.6-113.3)
Male	15	9.5	157.8	(88.2-260.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.0	71.7	(23.1-167.4)	Female	22	23.0	95.5	(59.8-144.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	8.6	69.9	(25.5-152.2)	Male	355	330.9	107.3	(96.4-119.1)
Female	1	2.7	nc	(nc-nc)	Female	324	331.4	97.8	(87.4-109.0)
<u>Lung and Bronchus</u>									
Male	21	44.9	46.8	(28.9-71.5)					
Female	44	46.9	93.9	(68.2-126.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	34.0	117.7	(84.1-160.3)	Male	14	21.4	65.5	(35.8-109.9)
Female	20	12.7	157.1	(95.9-242.6)	Female	16	17.1	93.8	(53.6-152.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.8	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
Female	9	5.2	172.4	(78.7-327.3)	Female	3	5.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	22	18.8	117.2	(73.4-177.5)
Female	144	131.9	109.2	(92.1-128.5)	Female	17	16.6	102.1	(59.4-163.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.4	nc	(nc-nc)	Male	22	14.7	149.4	(93.6-226.2)
<u>Colon / Rectum</u>					Female	7	6.9	101.7	(40.7-209.5)
Male	43	36.5	117.7	(85.2-158.5)	<u>Ovary</u>				
Female	40	38.1	104.9	(74.9-142.8)	Female	8	12.1	66.1	(28.4-130.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	8.9	157.6	(86.1-264.4)	Male	8	11.4	70.2	(30.2-138.3)
Female	4	2.5	nc	(nc-nc)	Female	12	12.4	97.0	(50.1-169.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.4	211.8	(68.2-494.2)	Male	97	117.6	82.5	(66.9-100.7)
Female	1	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	7.8	102.6	(44.2-202.1)
Male	27	17.5	153.9	(101.4-224.0)	Female	2	4.8	nc	(nc-nc)
Female	11	10.7	102.6	(51.2-183.6)	<u>Testis</u>				
<u>Larynx</u>					Male	9	3.8	239.8	(109.4-455.2)
Male	6	4.9	122.6	(44.8-266.9)	<u>Thyroid</u>				
Female	3	1.7	nc	(nc-nc)	Male	11	7.7	142.6	(71.1-255.1)
<u>Leukemia</u>					Female	18	23.0	78.3	(46.4-123.7)
Male	18	12.9	139.3	(82.5-220.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	9.8	51.2	(16.5-119.6)	Female	27	30.4	88.9	(58.6-129.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	11.0	126.7	(69.2-212.7)	Male	468	439.7	106.4	(97.0-116.5)
Female	4	3.8	nc	(nc-nc)	Female	495	454.2	109.0	(99.6-119.0)
<u>Lung and Bronchus</u>									
Male	67	61.3	109.2	(84.6-138.7)					
Female	90	66.3	135.8	(109.2-167.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	13.2	37.9	(12.2-88.6)
Female	0	0.1	nc	(nc-nc)	Female	8	9.8	81.9	(35.3-161.3)
<u>Lung and Bronchus</u>									
Male	1	1.8	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	23.5	110.5	(72.2-161.9)	Male	39	14.8	264.1	(187.8-361.1)
Female	12	8.4	143.3	(74.0-250.4)	Female	32	11.2	284.5	(194.6-401.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.1	122.2	(39.4-285.3)	Male	5	4.4	112.9	(36.4-263.5)
Female	3	3.5	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	11	13.0	84.7	(42.2-151.6)
Female	98	90.1	108.8	(88.3-132.6)	Female	9	11.1	81.4	(37.1-154.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.9	nc	(nc-nc)	Male	17	10.4	163.7	(95.3-262.1)
<u>Colon / Rectum</u>					Female	6	4.6	129.9	(47.4-282.8)
Male	21	25.5	82.3	(50.9-125.9)	<u>Ovary</u>				
Female	18	25.4	71.0	(42.0-112.2)	Female	8	8.2	98.1	(42.2-193.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	6.2	96.3	(35.2-209.7)	Male	8	7.9	100.7	(43.3-198.4)
Female	0	1.6	nc	(nc-nc)	Female	9	8.1	110.6	(50.5-210.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.5	nc	(nc-nc)	Male	63	83.1	75.8	(58.3-97.0)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	5.4	129.0	(51.7-265.8)
Male	6	12.3	48.8	(17.8-106.3)	Female	3	3.2	nc	(nc-nc)
Female	6	7.2	83.3	(30.4-181.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.1	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.1	nc	(nc-nc)	Male	2	5.3	nc	(nc-nc)
<u>Leukemia</u>					Female	19	15.2	124.7	(75.0-194.8)
Male	9	9.0	100.2	(45.7-190.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	6.5	122.9	(52.9-242.2)	Female	14	20.6	67.8	(37.1-113.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	7.8	nc	(nc-nc)	Male	295	306.7	96.2	(85.5-107.8)
Female	2	2.5	nc	(nc-nc)	Female	321	304.4	105.5	(94.2-117.7)
<u>Lung and Bronchus</u>									
Male	37	42.7	86.7	(61.0-119.5)					
Female	47	43.9	107.1	(78.7-142.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	16.7	113.5	(68.3-177.2)	Male	11	10.8	101.7	(50.7-182.0)
Female	2	5.4	nc	(nc-nc)	Female	8	8.0	100.0	(43.1-197.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.0	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	12	9.5	126.4	(65.2-220.7)
Female	59	63.0	93.6	(71.3-120.8)	Female	5	7.5	67.1	(21.6-156.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	5	7.7	64.9	(20.9-151.4)
<u>Colon / Rectum</u>					Female	5	3.2	158.1	(50.9-368.9)
Male	10	18.4	54.3	(26.0-99.8)	<u>Ovary</u>				
Female	10	16.7	59.9	(28.7-110.2)	Female	6	5.7	105.5	(38.5-229.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.5	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	7	5.3	133.0	(53.3-274.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	42	61.0	68.8	(49.6-93.1)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.9	127.6	(41.1-297.8)
Male	7	9.1	76.9	(30.8-158.5)	Female	1	2.1	nc	(nc-nc)
Female	1	4.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.9	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<u>Leukemia</u>					Female	13	11.6	111.9	(59.5-191.3)
Male	7	6.5	108.1	(43.3-222.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.3	nc	(nc-nc)	Female	9	14.5	62.1	(28.3-117.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.7	nc	(nc-nc)	Male	170	223.5	76.1	(65.1-88.4)
Female	0	1.7	nc	(nc-nc)	Female	179	208.7	85.8	(73.7-99.3)
<u>Lung and Bronchus</u>									
Male	19	30.6	62.0	(37.3-96.8)					
Female	32	29.0	110.3	(75.4-155.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	19.0	73.8	(40.3-123.8)	Male	14	12.7	110.5	(60.4-185.4)
Female	5	6.4	78.6	(25.3-183.4)	Female	13	9.7	134.0	(71.3-229.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.7	nc	(nc-nc)	Male	8	3.7	213.5	(91.9-420.6)
Female	2	3.1	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	18	11.2	161.2	(95.5-254.7)
Female	87	77.4	112.4	(90.1-138.7)	Female	8	8.9	89.7	(38.6-176.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	6	9.5	62.9	(23.0-136.9)
<u>Colon / Rectum</u>					Female	1	3.8	nc	(nc-nc)
Male	13	21.7	59.9	(31.9-102.5)	<u>Ovary</u>				
Female	12	19.8	60.7	(31.3-106.0)	Female	9	6.9	129.5	(59.1-245.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.4	nc	(nc-nc)	Male	10	6.6	150.5	(72.1-276.9)
Female	2	1.2	nc	(nc-nc)	Female	8	6.2	130.0	(56.0-256.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	72	73.7	97.7	(76.5-123.1)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.6	nc	(nc-nc)
Male	6	11.0	54.7	(20.0-119.2)	Female	1	2.4	nc	(nc-nc)
Female	5	5.9	84.6	(27.3-197.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.1	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	8	5.0	160.0	(68.9-315.4)
<u>Leukemia</u>					Female	30	14.5	207.3	(139.8-295.9)
Male	4	7.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	5.2	nc	(nc-nc)	Female	12	17.9	67.1	(34.7-117.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	7.0	nc	(nc-nc)	Male	226	264.0	85.6	(74.8-97.5)
Female	2	2.0	nc	(nc-nc)	Female	256	252.0	101.6	(89.5-114.8)
<u>Lung and Bronchus</u>									
Male	13	35.0	37.1	(19.8-63.5)					
Female	32	34.0	94.2	(64.4-133.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.8	104.2	(33.6-243.3)	Male	4	3.0	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	22	17.2	128.1	(80.2-193.9)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	<u>Ovary</u>				
Female	3	4.9	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	17	17.3	98.3	(57.3-157.5)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.1	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.8	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.2	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	46	62.7	73.3	(53.7-97.8)
Female	1	0.5	nc	(nc-nc)	Female	64	58.8	108.9	(83.9-139.1)
<u>Lung and Bronchus</u>									
Male	5	8.7	57.2	(18.4-133.6)					
Female	16	8.6	185.5	(106.0-301.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.7	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	8	10.1	79.1	(34.1-155.9)	Female	3	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	16	10.1	158.5	(90.5-257.4)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.6	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	7	2.4	289.4	(116.0-596.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	41	36.1	113.6	(81.5-154.2)
Female	0	0.3	nc	(nc-nc)	Female	41	35.1	116.7	(83.7-158.3)
<u>Lung and Bronchus</u>									
Male	4	5.0	nc	(nc-nc)					
Female	3	5.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	4.8	144.7	(58.0-298.1)	Male	5	3.2	157.9	(50.9-368.5)
Female	1	1.5	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	21	18.8	111.8	(69.2-170.9)	Female	3	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	8	5.5	146.6	(63.1-288.9)	<u>Ovary</u>				
Female	3	4.7	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.4	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	20	18.4	108.9	(66.5-168.1)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.3	149.8	(48.3-349.5)
Male	4	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.2	nc	(nc-nc)	Female	5	4.3	116.1	(37.4-271.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	65	66.2	98.2	(75.8-125.2)
Female	0	0.5	nc	(nc-nc)	Female	62	60.3	102.9	(78.9-131.9)
<u>Lung and Bronchus</u>									
Male	3	9.0	nc	(nc-nc)					
Female	7	8.3	84.7	(34.0-174.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	6.4	124.7	(53.7-245.8)	Male	4	4.9	nc	(nc-nc)
Female	5	2.0	253.9	(81.8-592.4)	Female	0	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	23	24.3	94.5	(59.9-141.8)	Female	0	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	13	7.9	164.6	(87.5-281.4)	<u>Ovary</u>				
Female	9	6.2	146.2	(66.7-277.5)	Female	2	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.9	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	24	24.8	96.7	(61.9-143.9)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	7	4.2	167.6	(67.2-345.4)	Female	2	0.8	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.7	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.8	nc	(nc-nc)
Male	0	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.6	nc	(nc-nc)	Female	12	5.5	216.3	(111.7-377.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	2.5	314.6	(135.5-619.9)	Male	110	95.1	115.7	(95.1-139.5)
Female	0	0.6	nc	(nc-nc)	Female	86	79.2	108.6	(86.8-134.1)
<u>Lung and Bronchus</u>									
Male	23	11.8	195.2	(123.7-292.9)					
Female	15	10.5	142.8	(79.8-235.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	36.3	118.4	(85.7-159.5)	Male	11	23.9	46.1	(23.0-82.4)
Female	10	13.5	74.2	(35.5-136.5)	Female	20	19.3	103.4	(63.1-159.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	7.1	127.1	(58.0-241.2)	Male	10	6.9	144.2	(69.1-265.3)
Female	3	6.1	nc	(nc-nc)	Female	5	5.7	87.6	(28.2-204.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	32	21.2	150.9	(103.2-213.1)
Female	151	147.4	102.5	(86.8-120.2)	Female	12	18.1	66.5	(34.3-116.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.3	nc	(nc-nc)	Male	13	16.8	77.5	(41.2-132.6)
<u>Colon / Rectum</u>					Female	5	7.5	66.9	(21.5-156.0)
Male	38	40.7	93.3	(66.0-128.1)	<u>Ovary</u>				
Female	34	41.8	81.3	(56.3-113.7)	Female	12	13.3	90.3	(46.6-157.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	9.6	145.8	(79.7-244.7)	Male	13	12.3	105.6	(56.2-180.6)
Female	2	2.6	nc	(nc-nc)	Female	8	13.2	60.8	(26.2-119.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.0	nc	(nc-nc)	Male	130	125.8	103.3	(86.3-122.7)
Female	5	2.4	204.3	(65.8-476.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	8.6	58.5	(18.8-136.5)
Male	30	19.9	150.6	(101.6-215.1)	Female	2	5.3	nc	(nc-nc)
Female	11	11.6	94.5	(47.1-169.0)	<u>Testis</u>				
<u>Larynx</u>					Male	7	5.0	138.7	(55.6-285.7)
Male	2	5.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.7	nc	(nc-nc)	Male	15	9.4	160.0	(89.5-263.9)
<u>Leukemia</u>					Female	17	28.3	60.1	(35.0-96.3)
Male	12	14.7	81.5	(42.1-142.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	11.0	81.6	(37.2-154.8)	Female	25	32.4	77.2	(49.9-113.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	12.2	73.8	(33.7-140.1)	Male	495	482.7	102.5	(93.7-112.0)
Female	1	4.0	nc	(nc-nc)	Female	425	499.3	85.1	(77.2-93.6)
<u>Lung and Bronchus</u>									
Male	56	65.2	85.9	(64.9-111.5)					
Female	57	68.7	83.0	(62.9-107.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	6	8.0	75.2	(27.4-163.6)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	7.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.6	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	14	26.4	53.0	(29.0-89.0)
Female	0	0.2	nc	(nc-nc)	Female	17	24.5	69.5	(40.5-111.3)
<u>Lung and Bronchus</u>									
Male	1	3.4	nc	(nc-nc)					
Female	1	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	26.2	95.3	(61.7-140.8)	Male	13	15.8	82.3	(43.8-140.7)
Female	12	10.7	112.3	(58.0-196.1)	Female	8	12.7	62.9	(27.1-123.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.2	119.8	(38.6-279.6)	Male	2	4.7	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	13	14.0	93.0	(49.5-159.1)
Female	90	97.5	92.3	(74.2-113.5)	Female	12	13.2	90.6	(46.8-158.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.0	nc	(nc-nc)	Male	8	10.5	76.5	(32.9-150.7)
<u>Colon / Rectum</u>					Female	7	5.3	131.7	(52.7-271.3)
Male	25	27.5	91.0	(58.9-134.4)	<u>Ovary</u>				
Female	30	32.0	93.9	(63.3-134.0)	Female	10	9.1	109.9	(52.6-202.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.5	76.5	(24.6-178.4)	Male	12	8.6	139.5	(72.0-243.7)
Female	0	2.0	nc	(nc-nc)	Female	10	10.6	94.7	(45.3-174.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.6	nc	(nc-nc)	Male	88	84.4	104.3	(83.6-128.4)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	5.9	186.7	(93.1-334.1)
Male	16	12.6	126.6	(72.3-205.6)	Female	5	4.1	121.9	(39.3-284.5)
Female	9	8.2	109.8	(50.1-208.4)	<u>Testis</u>				
<u>Larynx</u>					Male	7	2.4	290.3	(116.3-598.2)
Male	4	3.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
<u>Leukemia</u>					Female	23	15.5	148.7	(94.2-223.2)
Male	11	9.7	113.4	(56.5-202.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	7.9	152.0	(78.5-265.6)	Female	26	22.0	118.4	(77.3-173.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	7.9	88.3	(35.4-181.9)	Male	335	324.4	103.3	(92.5-114.9)
Female	1	3.0	nc	(nc-nc)	Female	332	350.4	94.7	(84.8-105.5)
<u>Lung and Bronchus</u>									
Male	52	46.2	112.5	(84.0-147.5)					
Female	39	52.4	74.5	(53.0-101.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	50.6	85.0	(61.5-114.5)	Male	31	36.8	84.2	(57.2-119.5)
Female	20	20.1	99.6	(60.8-153.9)	Female	17	36.0	47.2	(27.5-75.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	12.1	66.1	(28.5-130.3)	Male	12	9.8	122.3	(63.1-213.7)
Female	14	10.5	133.6	(73.0-224.2)	Female	11	8.6	128.5	(64.0-229.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.6	nc	(nc-nc)	Male	37	32.6	113.4	(79.9-156.4)
Female	190	224.0	84.8	(73.2-97.8)	Female	19	28.4	66.9	(40.3-104.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	10.2	78.7	(33.9-155.0)	Male	29	24.9	116.4	(78.0-167.2)
<u>Colon / Rectum</u>					Female	8	11.6	69.2	(29.8-136.4)
Male	55	58.2	94.5	(71.2-123.0)	<u>Ovary</u>				
Female	56	62.6	89.5	(67.6-116.2)	Female	22	21.3	103.4	(64.8-156.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	13.6	88.4	(45.6-154.4)	Male	21	17.4	120.9	(74.8-184.9)
Female	6	3.9	155.8	(56.9-339.2)	Female	21	19.6	107.0	(66.2-163.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	15	7.7	194.7	(108.9-321.1)	Male	151	179.1	84.3	(71.4-98.9)
Female	4	6.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	12.2	139.7	(81.3-223.7)
Male	34	29.8	114.0	(79.0-159.3)	Female	11	7.9	138.9	(69.3-248.6)
Female	23	18.0	128.0	(81.1-192.0)	<u>Testis</u>				
<u>Larynx</u>					Male	7	16.8	41.8	(16.7-86.1)
Male	10	7.6	132.4	(63.4-243.6)	<u>Thyroid</u>				
Female	2	2.6	nc	(nc-nc)	Male	19	17.5	108.5	(65.3-169.4)
<u>Leukemia</u>					Female	53	58.8	90.1	(67.5-117.8)
Male	19	22.7	83.8	(50.4-130.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	17.8	106.6	(64.2-166.5)	Female	46	49.6	92.8	(67.9-123.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	17.6	142.4	(92.2-210.3)	Male	706	714.7	98.8	(91.6-106.4)
Female	13	6.1	214.2	(113.9-366.3)	Female	727	789.6	92.1	(85.5-99.0)
<u>Lung and Bronchus</u>									
Male	111	90.6	122.5	(100.8-147.5)					
Female	103	103.2	99.8	(81.4-121.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	21.4	88.8	(53.4-138.7)	Male	22	13.0	169.3	(106.1-256.3)
Female	13	8.4	154.0	(81.9-263.3)	Female	9	11.1	80.9	(36.9-153.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.5	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	12	11.5	104.4	(53.9-182.3)
Female	97	81.5	119.0	(96.5-145.2)	Female	10	10.8	92.3	(44.2-169.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.7	188.2	(60.6-439.2)	Male	5	8.7	57.1	(18.4-133.4)
<u>Colon / Rectum</u>					Female	7	4.4	159.1	(63.7-327.7)
Male	22	22.6	97.2	(60.9-147.2)	<u>Ovary</u>				
Female	31	25.5	121.7	(82.7-172.7)	Female	5	7.7	64.8	(20.9-151.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.4	92.7	(29.9-216.2)	Male	5	7.1	70.8	(22.8-165.3)
Female	3	1.6	nc	(nc-nc)	Female	8	8.3	96.4	(41.5-190.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	74	70.0	105.6	(82.9-132.6)
Female	0	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	4.8	165.6	(71.3-326.3)
Male	8	10.4	76.6	(33.0-151.0)	Female	2	3.2	nc	(nc-nc)
Female	6	6.8	88.9	(32.4-193.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.0	nc	(nc-nc)
Male	8	2.9	271.4	(116.9-534.8)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	10	14.7	67.9	(32.5-124.9)
Male	5	8.0	62.7	(20.2-146.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	6.6	106.7	(42.7-219.8)	Female	24	18.5	129.8	(83.2-193.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.6	nc	(nc-nc)	Male	263	267.4	98.4	(86.8-111.0)
Female	0	2.4	nc	(nc-nc)	Female	295	290.7	101.5	(90.2-113.7)
<u>Lung and Bronchus</u>									
Male	33	37.7	87.4	(60.2-122.8)					
Female	37	42.3	87.5	(61.6-120.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.3	79.1	(25.5-184.6)	Male	1	4.4	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	22	26.6	82.7	(51.8-125.2)	Female	1	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.3	nc	(nc-nc)
Male	9	7.3	123.0	(56.1-233.5)	<u>Ovary</u>				
Female	8	6.5	122.3	(52.6-240.9)	Female	3	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.9	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.5	nc	(nc-nc)	Male	25	26.7	93.7	(60.6-138.3)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.5	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.8	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	1	5.0	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.7	nc	(nc-nc)	Female	7	6.3	111.4	(44.6-229.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.5	nc	(nc-nc)	Male	75	91.7	81.8	(64.3-102.5)
Female	0	0.7	nc	(nc-nc)	Female	71	86.0	82.6	(64.5-104.2)
<u>Lung and Bronchus</u>									
Male	5	11.9	41.8	(13.5-97.6)					
Female	11	11.7	94.4	(47.1-168.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	9.0	134.0	(69.2-234.1)	Male	6	6.3	95.5	(34.9-207.9)
Female	2	3.1	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.0	nc	(nc-nc)	Male	5	1.8	273.4	(88.1-638.1)
Female	0	1.6	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
Female	45	39.7	113.3	(82.6-151.6)	Female	4	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	8	4.8	166.8	(71.8-328.8)
<u>Colon / Rectum</u>					Female	2	1.9	nc	(nc-nc)
Male	6	10.6	56.6	(20.7-123.2)	<u>Ovary</u>				
Female	13	9.6	135.0	(71.8-230.9)	Female	2	3.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.6	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	6	2.9	203.4	(74.3-442.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	42	35.7	117.5	(84.7-158.9)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.2	nc	(nc-nc)
Male	6	5.5	108.1	(39.5-235.3)	Female	0	1.2	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.2	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.7	188.3	(60.7-439.4)
<u>Leukemia</u>					Female	5	7.7	65.0	(21.0-151.8)
Male	4	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.6	nc	(nc-nc)	Female	8	8.9	90.3	(38.9-178.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.4	nc	(nc-nc)	Male	138	129.1	106.9	(89.8-126.3)
Female	0	1.0	nc	(nc-nc)	Female	128	126.6	101.1	(84.4-120.2)
<u>Lung and Bronchus</u>									
Male	11	16.9	65.3	(32.5-116.8)					
Female	19	16.9	112.6	(67.8-175.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	16.8	112.8	(67.9-176.1)	Male	6	10.9	54.8	(20.0-119.3)
Female	9	6.7	134.1	(61.2-254.6)	Female	4	9.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	9.7	92.3	(42.1-175.3)
Female	68	69.0	98.6	(76.5-124.9)	Female	10	8.8	113.5	(54.3-208.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	12	7.7	156.3	(80.7-273.1)
<u>Colon / Rectum</u>					Female	2	3.6	nc	(nc-nc)
Male	19	18.7	101.7	(61.2-158.8)	<u>Ovary</u>				
Female	20	20.6	96.9	(59.1-149.6)	Female	6	6.4	93.6	(34.2-203.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.4	nc	(nc-nc)	Male	5	5.7	87.6	(28.2-204.4)
Female	1	1.3	nc	(nc-nc)	Female	3	6.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	43	58.8	73.1	(52.9-98.5)
Female	3	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.9	152.4	(55.6-331.7)
Male	11	9.1	121.4	(60.5-217.2)	Female	5	2.6	190.3	(61.3-444.0)
Female	11	5.6	197.3	(98.3-353.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	5	2.4	204.6	(65.9-477.4)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	0	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	13.1	53.6	(21.5-110.4)
Male	6	6.8	87.7	(32.0-191.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	5.4	184.7	(88.4-339.7)	Female	15	15.6	96.3	(53.8-158.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.6	106.6	(38.9-232.1)	Male	220	223.3	98.5	(85.9-112.4)
Female	0	2.0	nc	(nc-nc)	Female	233	240.1	97.0	(85.0-110.3)
<u>Lung and Bronchus</u>									
Male	40	30.0	133.5	(95.4-181.8)					
Female	33	33.3	99.2	(68.3-139.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.7	93.4	(44.7-171.7)	Male	5	7.1	70.4	(22.7-164.3)
Female	3	4.0	nc	(nc-nc)	Female	4	5.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	6.3	nc	(nc-nc)
Female	32	43.1	74.2	(50.8-104.8)	Female	7	5.3	132.9	(53.2-273.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.2	nc	(nc-nc)
Male	7	12.2	57.5	(23.0-118.5)	<u>Ovary</u>				
Female	15	12.3	122.2	(68.4-201.6)	Female	4	3.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.9	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	37	39.9	92.7	(65.3-127.8)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.6	nc	(nc-nc)
Male	6	6.0	99.3	(36.2-216.0)	Female	1	1.5	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.3	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	7.8	nc	(nc-nc)
Male	1	4.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.1	159.2	(51.3-371.4)	Female	5	9.7	51.8	(16.7-120.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.8	nc	(nc-nc)	Male	116	146.3	79.3	(65.5-95.1)
Female	2	1.2	nc	(nc-nc)	Female	111	145.6	76.2	(62.7-91.8)
<u>Lung and Bronchus</u>									
Male	15	19.5	76.8	(43.0-126.8)					
Female	11	20.3	54.1	(27.0-96.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	13.3	143.1	(86.1-223.5)	Male	5	8.7	57.2	(18.4-133.5)
Female	12	4.5	268.0	(138.3-468.2)	Female	4	6.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.5	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.7	65.2	(21.0-152.1)
Female	45	50.6	89.0	(64.9-119.0)	Female	6	6.1	98.3	(35.9-214.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	6	6.3	95.1	(34.7-207.0)
<u>Colon / Rectum</u>					Female	3	2.6	nc	(nc-nc)
Male	12	14.8	81.2	(41.9-141.9)	<u>Ovary</u>				
Female	17	13.6	125.2	(72.9-200.5)	Female	2	4.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.7	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	25	49.8	50.2	(32.5-74.2)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	12	7.4	162.1	(83.6-283.1)	Female	2	1.7	nc	(nc-nc)
Female	7	4.0	175.6	(70.4-361.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	9.5	nc	(nc-nc)
Male	14	5.3	265.9	(145.2-446.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.6	139.3	(44.9-325.1)	Female	15	11.7	127.7	(71.4-210.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.7	107.0	(34.5-249.8)	Male	153	180.8	84.6	(71.7-99.1)
Female	2	1.4	nc	(nc-nc)	Female	166	169.6	97.9	(83.5-113.9)
<u>Lung and Bronchus</u>									
Male	26	24.4	106.4	(69.5-156.0)					
Female	19	23.7	80.2	(48.3-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	97	123.0	78.9	(64.0-96.2)	Male	33	82.0	40.2	(27.7-56.5)
Female	40	49.1	81.5	(58.2-111.0)	Female	34	75.5	45.0	(31.2-62.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	28	26.3	106.5	(70.8-154.0)	Male	22	23.5	93.5	(58.6-141.5)
Female	24	24.3	98.7	(63.2-146.8)	Female	17	21.0	80.9	(47.1-129.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	8	3.9	204.7	(88.1-403.3)	Male	68	73.4	92.6	(71.9-117.4)
Female	528	548.2	96.3	(88.3-104.9)	Female	62	67.5	91.8	(70.4-117.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	31	20.6	150.8	(102.4-214.0)	Male	64	57.9	110.6	(85.2-141.3)
<u>Colon / Rectum</u>					Female	21	28.1	74.7	(46.2-114.1)
Male	148	137.6	107.6	(91.0-126.4)	<u>Ovary</u>				
Female	151	151.2	99.8	(84.5-117.1)	Female	39	50.6	77.1	(54.8-105.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	37	33.0	112.2	(79.0-154.7)	Male	42	42.0	100.1	(72.1-135.3)
Female	13	9.4	137.9	(73.4-235.8)	Female	41	47.8	85.8	(61.6-116.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	11	12.4	88.7	(44.2-158.6)	Male	452	439.6	102.8	(93.6-112.8)
Female	15	11.5	130.3	(72.9-215.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	38	29.0	131.1	(92.8-179.9)
Male	81	68.4	118.4	(94.0-147.1)	Female	24	19.0	126.3	(80.9-187.9)
Female	47	43.7	107.5	(79.0-143.0)	<u>Testis</u>				
<u>Larynx</u>					Male	13	21.8	59.5	(31.7-101.8)
Male	19	18.3	103.9	(62.5-162.3)	<u>Thyroid</u>				
Female	8	6.6	120.8	(52.0-238.1)	Male	14	33.5	41.8	(22.9-70.2)
<u>Leukemia</u>					Female	74	113.8	65.0	(51.1-81.7)
Male	48	52.7	91.0	(67.1-120.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	43	42.3	101.6	(73.5-136.9)	Female	116	124.1	93.4	(77.2-112.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	67	42.4	157.9	(122.4-200.6)	Male	1657	1672.5	99.1	(94.4-104.0)
Female	11	15.1	73.1	(36.4-130.8)	Female	1735	1872.6	92.7	(88.3-97.1)
<u>Lung and Bronchus</u>									
Male	248	221.6	111.9	(98.4-126.7)					
Female	258	254.8	101.3	(89.3-114.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.5	118.0	(56.5-217.1)	Male	5	5.7	87.4	(28.2-203.9)
Female	4	3.0	nc	(nc-nc)	Female	5	4.5	111.6	(36.0-260.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.0	139.3	(55.8-287.1)
Female	34	35.3	96.4	(66.8-134.8)	Female	3	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.8	nc	(nc-nc)
Male	7	9.7	72.1	(28.9-148.5)	<u>Ovary</u>				
Female	7	9.5	73.7	(29.5-151.8)	Female	5	3.2	156.4	(50.4-365.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.4	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	46	33.5	137.3	(100.5-183.1)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	5	5.0	100.5	(32.4-234.5)	Female	1	1.2	nc	(nc-nc)
Female	6	2.7	221.1	(80.7-481.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.0	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.5	108.1	(43.3-222.7)
Male	5	3.4	146.4	(47.2-341.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.5	nc	(nc-nc)	Female	10	8.1	122.9	(58.8-226.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.2	nc	(nc-nc)	Male	120	119.2	100.7	(83.5-120.4)
Female	0	0.9	nc	(nc-nc)	Female	107	116.6	91.8	(75.2-110.9)
<u>Lung and Bronchus</u>									
Male	9	15.8	57.0	(26.0-108.3)					
Female	12	15.6	76.8	(39.6-134.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.5	nc	(nc-nc)	Male	5	2.1	234.5	(75.6-547.3)
Female	2	1.3	nc	(nc-nc)	Female	5	1.6	314.3	(101.3-733.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	10	12.7	78.5	(37.6-144.4)	Female	3	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	6	3.7	163.6	(59.8-356.2)	<u>Ovary</u>				
Female	6	3.8	156.0	(57.0-339.5)	Female	2	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	13	12.9	100.6	(53.5-172.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.9	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	47	45.5	103.3	(75.9-137.4)
Female	0	0.4	nc	(nc-nc)	Female	46	44.7	102.9	(75.3-137.2)
<u>Lung and Bronchus</u>									
Male	2	6.5	nc	(nc-nc)					
Female	2	6.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	28.1	78.2	(49.0-118.5)	Male	13	17.4	74.6	(39.7-127.6)
Female	14	11.1	126.1	(68.9-211.6)	Female	19	14.2	133.8	(80.5-208.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.7	nc	(nc-nc)	Male	6	5.2	115.8	(42.3-252.0)
Female	4	4.4	nc	(nc-nc)	Female	5	4.6	108.2	(34.9-252.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	19	15.4	123.7	(74.5-193.2)
Female	127	108.8	116.7	(97.3-138.8)	Female	13	14.2	91.7	(48.8-156.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	3.6	253.2	(115.5-480.6)	Male	13	11.8	109.7	(58.4-187.6)
<u>Colon / Rectum</u>					Female	7	5.8	120.9	(48.4-249.1)
Male	33	30.1	109.7	(75.5-154.1)	<u>Ovary</u>				
Female	34	33.5	101.6	(70.4-142.0)	Female	11	10.1	109.3	(54.5-195.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.2	111.0	(47.8-218.7)	Male	3	9.4	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	13	10.9	119.4	(63.5-204.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.9	nc	(nc-nc)	Male	79	94.4	83.7	(66.3-104.3)
Female	3	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	6.4	187.3	(96.7-327.3)
Male	17	14.1	120.2	(70.0-192.4)	Female	5	4.3	117.6	(37.9-274.5)
Female	10	8.9	111.8	(53.5-205.6)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.9	nc	(nc-nc)
Male	6	4.0	151.8	(55.4-330.3)	<u>Thyroid</u>				
Female	2	1.4	nc	(nc-nc)	Male	11	6.1	178.9	(89.2-320.2)
<u>Leukemia</u>					Female	23	18.5	124.6	(78.9-186.9)
Male	16	10.6	150.3	(85.8-244.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.4	118.7	(56.8-218.3)	Female	32	24.7	129.6	(88.6-183.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	8.9	89.6	(38.6-176.5)	Male	368	357.7	102.9	(92.6-113.9)
Female	4	3.2	nc	(nc-nc)	Female	418	381.8	109.5	(99.2-120.5)
<u>Lung and Bronchus</u>									
Male	46	50.1	91.8	(67.2-122.5)					
Female	47	55.7	84.3	(62.0-112.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	31.3	89.5	(59.4-129.3)	Male	16	20.0	79.8	(45.6-129.6)
Female	13	12.3	105.6	(56.2-180.6)	Female	24	16.7	143.5	(91.9-213.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.7	105.4	(38.5-229.5)	Male	4	5.9	nc	(nc-nc)
Female	6	5.1	116.5	(42.6-253.7)	Female	6	5.2	115.0	(42.0-250.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	15	17.7	84.7	(47.4-139.7)
Female	142	129.2	109.9	(92.6-129.6)	Female	23	16.2	141.9	(89.9-212.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.3	115.0	(37.1-268.5)	Male	19	14.1	134.3	(80.8-209.8)
<u>Colon / Rectum</u>					Female	7	6.7	104.4	(41.8-215.0)
Male	36	34.3	104.8	(73.4-145.2)	<u>Ovary</u>				
Female	43	37.2	115.7	(83.7-155.9)	Female	15	11.8	126.9	(70.9-209.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	8.3	107.8	(49.2-204.7)	Male	11	10.6	103.5	(51.6-185.2)
Female	7	2.4	295.1	(118.2-608.1)	Female	16	12.0	133.3	(76.1-216.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.3	214.1	(69.0-499.5)	Male	107	111.6	95.9	(78.6-115.9)
Female	6	2.0	301.0	(109.9-655.1)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.3	82.4	(30.1-179.3)
Male	23	16.7	137.5	(87.2-206.4)	Female	10	4.7	214.4	(102.6-394.3)
Female	16	10.4	153.5	(87.7-249.3)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.8	nc	(nc-nc)
Male	10	4.6	217.7	(104.2-400.4)	<u>Thyroid</u>				
Female	2	1.6	nc	(nc-nc)	Male	10	7.5	132.7	(63.5-244.1)
<u>Leukemia</u>					Female	37	22.9	161.7	(113.9-222.9)
Male	8	12.2	65.4	(28.1-128.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	9.6	62.6	(22.9-136.3)	Female	22	29.6	74.4	(46.6-112.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	10.4	47.9	(15.4-111.7)	Male	425	413.7	102.7	(93.2-113.0)
Female	1	3.7	nc	(nc-nc)	Female	513	443.1	115.8	(106.0-126.2)
<u>Lung and Bronchus</u>									
Male	68	56.5	120.3	(93.4-152.5)					
Female	63	63.8	98.7	(75.8-126.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	7.2	139.3	(66.7-256.2)	Male	3	4.8	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	32	29.1	109.8	(75.1-155.0)	Female	5	3.3	153.8	(49.6-359.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.4	nc	(nc-nc)
Male	5	8.2	61.0	(19.7-142.4)	<u>Ovary</u>				
Female	6	7.0	85.1	(31.1-185.3)	Female	6	2.6	233.4	(85.2-508.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.0	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	36	27.7	130.1	(91.1-180.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	5.5	nc	(nc-nc)
Male	5	2.9	172.1	(55.5-401.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.9	nc	(nc-nc)	Female	9	6.7	134.7	(61.4-255.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.6	nc	(nc-nc)	Male	91	99.7	91.2	(73.5-112.0)
Female	1	0.7	nc	(nc-nc)	Female	100	93.2	107.3	(87.3-130.5)
<u>Lung and Bronchus</u>									
Male	3	13.3	nc	(nc-nc)					
Female	12	12.6	95.3	(49.2-166.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	10.5	133.3	(72.8-223.6)	Male	9	6.8	131.6	(60.0-249.8)
Female	6	3.6	168.3	(61.4-366.3)	Female	6	5.2	115.3	(42.1-251.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
Female	42	40.5	103.7	(74.8-140.2)	Female	5	4.9	103.0	(33.2-240.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.0	nc	(nc-nc)
Male	10	11.6	86.1	(41.2-158.4)	<u>Ovary</u>				
Female	5	10.8	46.1	(14.9-107.7)	Female	2	3.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.9	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	6	3.5	173.7	(63.4-378.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.8	nc	(nc-nc)	Male	41	38.7	106.1	(76.1-143.9)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.5	nc	(nc-nc)
Male	7	5.8	120.7	(48.4-248.8)	Female	2	1.3	nc	(nc-nc)
Female	6	3.2	187.8	(68.6-408.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.3	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	7.6	66.0	(21.3-154.0)
Male	4	4.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.9	nc	(nc-nc)	Female	20	9.3	215.5	(131.6-332.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.6	nc	(nc-nc)	Male	137	141.5	96.9	(81.3-114.5)
Female	2	1.1	nc	(nc-nc)	Female	139	135.3	102.7	(86.4-121.3)
<u>Lung and Bronchus</u>									
Male	18	19.2	93.6	(55.4-147.9)					
Female	15	18.9	79.2	(44.3-130.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	17.9	89.5	(51.1-145.3)	Male	21	12.0	174.5	(108.0-266.8)
Female	2	6.0	nc	(nc-nc)	Female	11	9.2	120.1	(59.9-214.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.6	192.1	(77.0-395.9)	Male	4	3.6	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	10.7	112.7	(58.1-196.8)
Female	112	74.2	150.9	(124.2-181.6)	Female	12	8.4	142.4	(73.5-248.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	4	9.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	3.6	nc	(nc-nc)
Male	22	20.6	106.6	(66.8-161.5)	<u>Ovary</u>				
Female	11	18.9	58.3	(29.0-104.3)	Female	5	6.6	76.2	(24.6-177.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.0	nc	(nc-nc)	Male	7	6.2	112.1	(44.9-231.0)
Female	0	1.2	nc	(nc-nc)	Female	4	5.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	76	68.4	111.1	(87.5-139.0)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.3	nc	(nc-nc)
Male	11	10.5	105.2	(52.4-188.2)	Female	2	2.3	nc	(nc-nc)
Female	6	5.6	106.6	(38.9-232.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.0	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	5	4.8	104.2	(33.6-243.2)
<u>Leukemia</u>					Female	15	13.8	108.3	(60.6-178.6)
Male	8	7.3	109.0	(46.9-214.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	5.1	157.7	(67.9-310.7)	Female	14	16.6	84.3	(46.0-141.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.6	nc	(nc-nc)	Male	228	249.0	91.6	(80.1-104.3)
Female	3	1.9	nc	(nc-nc)	Female	281	239.6	117.3	(104.0-131.8)
<u>Lung and Bronchus</u>									
Male	11	33.1	33.3	(16.6-59.5)					
Female	35	32.0	109.2	(76.1-151.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.0	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	13	12.9	100.9	(53.7-172.6)	Female	0	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	<u>Ovary</u>				
Female	0	3.5	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	14	11.3	124.4	(67.9-208.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.8	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.9	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	40	42.2	94.7	(67.6-129.0)
Female	0	0.3	nc	(nc-nc)	Female	24	43.6	55.0	(35.3-81.9)
<u>Lung and Bronchus</u>									
Male	4	5.4	nc	(nc-nc)					
Female	1	5.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.7	115.3	(55.2-212.0)	Male	10	6.1	163.4	(78.2-300.5)
Female	5	2.7	182.9	(58.9-426.8)	Female	4	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	7	5.4	130.3	(52.2-268.5)
Female	40	36.7	108.9	(77.8-148.3)	Female	5	4.0	124.5	(40.1-290.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	1	4.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	1.8	285.4	(92.0-666.0)
Male	7	10.2	68.3	(27.4-140.7)	<u>Ovary</u>				
Female	8	8.6	92.9	(40.0-183.0)	Female	1	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.6	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	30	36.8	81.6	(55.0-116.5)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	7	5.5	127.7	(51.2-263.2)	Female	2	1.1	nc	(nc-nc)
Female	5	2.7	183.2	(59.0-427.5)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	8	7.3	109.2	(47.0-215.1)
Male	5	3.6	138.0	(44.5-322.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.4	nc	(nc-nc)	Female	14	8.4	166.2	(90.8-278.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.4	nc	(nc-nc)	Male	123	127.8	96.2	(80.0-114.8)
Female	0	0.9	nc	(nc-nc)	Female	123	116.2	105.8	(88.0-126.3)
<u>Lung and Bronchus</u>									
Male	17	16.5	103.2	(60.1-165.3)					
Female	13	15.2	85.8	(45.6-146.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	18.1	121.7	(76.2-184.2)	Male	11	11.1	98.8	(49.2-176.8)
Female	14	7.1	198.4	(108.4-333.0)	Female	12	9.1	131.9	(68.1-230.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.1	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	19	9.9	192.2	(115.7-300.2)
Female	83	70.6	117.6	(93.6-145.7)	Female	12	9.1	132.5	(68.4-231.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	6	7.7	77.7	(28.4-169.1)
<u>Colon / Rectum</u>					Female	3	3.7	nc	(nc-nc)
Male	17	19.5	87.4	(50.9-139.9)	<u>Ovary</u>				
Female	25	21.6	115.7	(74.8-170.7)	Female	5	6.5	76.6	(24.7-178.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.7	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	7	7.0	100.2	(40.1-206.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	58	61.0	95.0	(72.2-122.8)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.1	nc	(nc-nc)
Male	11	9.1	120.9	(60.3-216.3)	Female	2	2.8	nc	(nc-nc)
Female	7	5.7	122.7	(49.2-252.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	8	3.9	204.8	(88.2-403.5)
<u>Leukemia</u>					Female	15	11.9	126.5	(70.7-208.6)
Male	6	6.9	86.9	(31.7-189.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	5.4	184.7	(88.4-339.7)	Female	23	16.1	143.2	(90.7-214.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.8	nc	(nc-nc)	Male	226	230.3	98.2	(85.8-111.8)
Female	2	2.0	nc	(nc-nc)	Female	287	245.0	117.1	(104.0-131.5)
<u>Lung and Bronchus</u>									
Male	32	31.9	100.3	(68.6-141.5)					
Female	36	34.7	103.8	(72.7-143.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	20.3	98.7	(60.2-152.4)	Male	9	12.9	69.8	(31.8-132.5)
Female	13	7.4	176.3	(93.8-301.4)	Female	4	9.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	5	3.0	164.5	(53.0-383.9)	Female	3	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	11.4	105.3	(54.4-184.0)
Female	75	77.3	97.0	(76.3-121.6)	Female	6	9.7	62.0	(22.6-134.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.6	193.1	(62.2-450.5)	Male	8	9.2	87.4	(37.6-172.3)
<u>Colon / Rectum</u>					Female	2	4.0	nc	(nc-nc)
Male	17	22.1	77.0	(44.8-123.3)	<u>Ovary</u>				
Female	19	22.3	85.1	(51.2-132.9)	Female	8	7.1	113.3	(48.8-223.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.4	129.1	(51.7-266.0)	Male	5	6.9	72.7	(23.4-169.6)
Female	0	1.4	nc	(nc-nc)	Female	8	7.2	111.0	(47.8-218.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.4	nc	(nc-nc)	Male	89	72.9	122.0	(98.0-150.1)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.7	106.1	(34.2-247.5)
Male	15	10.8	139.2	(77.8-229.6)	Female	3	2.8	nc	(nc-nc)
Female	4	6.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.2	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.0	nc	(nc-nc)	Male	1	4.8	nc	(nc-nc)
<u>Leukemia</u>					Female	9	13.5	66.7	(30.4-126.6)
Male	3	7.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.7	88.0	(28.4-205.4)	Female	17	17.7	95.8	(55.8-153.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.8	88.4	(32.3-192.5)	Male	261	267.5	97.6	(86.1-110.2)
Female	1	2.2	nc	(nc-nc)	Female	248	264.4	93.8	(82.5-106.2)
<u>Lung and Bronchus</u>									
Male	28	36.5	76.6	(50.9-110.8)					
Female	36	37.8	95.2	(66.7-131.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	53	55.2	96.0	(71.9-125.6)	Male	26	36.6	71.1	(46.4-104.2)
Female	25	21.5	116.1	(75.1-171.4)	Female	29	31.3	92.5	(62.0-132.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	10.9	82.7	(37.7-157.0)	Male	10	10.6	94.4	(45.2-173.7)
Female	6	9.7	62.0	(22.7-135.0)	Female	16	9.2	174.8	(99.9-283.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.8	nc	(nc-nc)	Male	40	32.4	123.6	(88.3-168.3)
Female	242	234.3	103.3	(90.7-117.1)	Female	41	28.9	141.7	(101.7-192.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	8.5	82.7	(33.1-170.5)	Male	32	25.9	123.7	(84.6-174.6)
<u>Colon / Rectum</u>					Female	10	12.0	83.3	(39.9-153.3)
Male	74	61.9	119.5	(93.9-150.1)	<u>Ovary</u>				
Female	90	66.3	135.7	(109.1-166.8)	Female	19	21.4	88.6	(53.3-138.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	17	14.8	114.8	(66.9-183.9)	Male	28	18.9	148.5	(98.7-214.7)
Female	3	4.1	nc	(nc-nc)	Female	25	21.1	118.7	(76.8-175.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	4.8	188.5	(86.0-357.8)	Male	183	196.7	93.0	(80.1-107.5)
Female	6	4.1	145.6	(53.2-316.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	13.0	130.5	(76.0-209.0)
Male	31	30.6	101.3	(68.8-143.8)	Female	7	8.3	83.9	(33.6-172.9)
Female	26	18.7	139.4	(91.0-204.2)	<u>Testis</u>				
<u>Larynx</u>					Male	11	8.3	132.1	(65.8-236.3)
Male	14	8.2	170.7	(93.3-286.5)	<u>Thyroid</u>				
Female	3	2.8	nc	(nc-nc)	Male	15	14.6	103.0	(57.6-169.9)
<u>Leukemia</u>					Female	75	45.5	164.9	(129.7-206.7)
Male	19	22.5	84.5	(50.9-132.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	17.6	73.9	(39.3-126.5)	Female	47	52.6	89.3	(65.6-118.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	20	18.9	105.8	(64.6-163.5)	Male	807	743.2	108.6	(101.2-116.3)
Female	5	6.5	77.4	(24.9-180.7)	Female	885	799.1	110.7	(103.6-118.3)
<u>Lung and Bronchus</u>									
Male	133	99.7	133.4	(111.7-158.1)					
Female	122	110.7	110.2	(91.5-131.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	9.0	122.0	(60.8-218.3)	Male	5	6.0	83.0	(26.7-193.7)
Female	3	2.9	nc	(nc-nc)	Female	0	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.8	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.3	94.2	(30.4-219.9)
Female	28	32.5	86.0	(57.1-124.3)	Female	4	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.2	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	9	10.2	88.4	(40.3-167.8)	<u>Ovary</u>				
Female	13	8.9	146.2	(77.8-250.0)	Female	6	3.0	203.2	(74.2-442.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.5	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	29	34.5	84.2	(56.4-120.9)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.2	nc	(nc-nc)
Male	7	5.2	135.0	(54.1-278.2)	Female	1	1.1	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.2	nc	(nc-nc)
Male	3	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.4	nc	(nc-nc)	Female	8	7.4	108.6	(46.8-214.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.2	nc	(nc-nc)	Male	115	124.6	92.3	(76.2-110.8)
Female	0	0.9	nc	(nc-nc)	Female	110	109.3	100.6	(82.7-121.3)
<u>Lung and Bronchus</u>									
Male	18	16.7	107.9	(63.9-170.5)					
Female	24	15.1	158.8	(101.7-236.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	32.3	136.1	(98.9-182.8)	Male	20	21.2	94.2	(57.5-145.4)
Female	11	11.6	94.7	(47.2-169.5)	Female	16	16.9	94.9	(54.2-154.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.1	114.5	(45.9-235.9)	Male	6	6.2	96.2	(35.1-209.4)
Female	4	5.2	nc	(nc-nc)	Female	5	5.0	100.0	(32.2-233.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.0	nc	(nc-nc)	Male	15	18.7	80.3	(44.9-132.4)
Female	136	131.8	103.2	(86.6-122.1)	Female	18	15.8	114.2	(67.6-180.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.6	153.1	(61.4-315.5)	Male	14	15.3	91.5	(50.0-153.6)
<u>Colon / Rectum</u>					Female	8	6.6	120.6	(51.9-237.6)
Male	35	36.0	97.1	(67.6-135.1)	<u>Ovary</u>				
Female	29	35.4	82.0	(54.9-117.8)	Female	15	11.9	126.0	(70.5-207.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	8.9	113.0	(54.1-207.8)	Male	15	11.1	134.9	(75.5-222.6)
Female	4	2.2	nc	(nc-nc)	Female	11	11.2	97.8	(48.8-175.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.5	nc	(nc-nc)	Male	117	119.6	97.8	(80.9-117.2)
Female	3	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.6	78.7	(28.7-171.3)
Male	29	18.0	161.1	(107.8-231.3)	Female	8	4.4	181.5	(78.1-357.6)
Female	9	10.3	87.0	(39.7-165.2)	<u>Testis</u>				
<u>Larynx</u>					Male	6	4.0	148.3	(54.2-322.9)
Male	6	4.9	122.3	(44.7-266.2)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	7	8.2	84.9	(34.0-175.0)
<u>Leukemia</u>					Female	26	24.3	106.9	(69.8-156.6)
Male	22	12.8	171.7	(107.6-260.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	9.3	161.7	(90.4-266.6)	Female	35	30.2	115.8	(80.7-161.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	11.2	71.2	(30.7-140.4)	Male	469	438.0	107.1	(97.6-117.2)
Female	1	3.6	nc	(nc-nc)	Female	493	439.6	112.2	(102.5-122.5)
<u>Lung and Bronchus</u>									
Male	62	59.3	104.6	(80.2-134.1)					
Female	88	61.5	143.1	(114.8-176.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.7	nc	(nc-nc)	Male	5	3.0	164.5	(53.0-383.8)
Female	0	1.9	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	31	19.6	157.9	(107.3-224.1)	Female	2	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.0	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	<u>Ovary</u>				
Female	6	5.6	107.1	(39.1-233.1)	Female	2	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.4	nc	(nc-nc)	Male	20	17.2	116.4	(71.1-179.8)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.1	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.4	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.4	nc	(nc-nc)	Female	5	4.6	108.6	(35.0-253.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.6	nc	(nc-nc)	Male	71	62.9	113.0	(88.2-142.5)
Female	0	0.6	nc	(nc-nc)	Female	74	67.3	109.9	(86.3-138.0)
<u>Lung and Bronchus</u>									
Male	4	8.4	nc	(nc-nc)					
Female	8	9.7	82.3	(35.4-162.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	10.1	59.3	(21.6-129.0)
Female	0	0.1	nc	(nc-nc)	Female	2	7.2	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	1	1.4	nc	(nc-nc)					
Female	0	1.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.0	99.7	(42.9-196.5)	Male	2	5.0	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	6	3.8	158.9	(58.0-345.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.4	157.6	(63.1-324.7)
Female	33	30.0	109.9	(75.7-154.4)	Female	4	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	5	8.7	57.2	(18.4-133.4)	<u>Ovary</u>				
Female	7	9.0	77.4	(31.0-159.4)	Female	5	2.7	182.2	(58.7-425.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.1	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	36	28.4	127.0	(88.9-175.8)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.9	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.9	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.3	nc	(nc-nc)	Female	8	6.8	118.2	(50.9-233.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.7	nc	(nc-nc)	Male	103	104.5	98.6	(80.5-119.6)
Female	1	0.9	nc	(nc-nc)	Female	106	103.1	102.8	(84.2-124.4)
<u>Lung and Bronchus</u>									
Male	12	14.4	83.1	(42.9-145.2)					
Female	15	14.6	102.4	(57.3-169.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	7.8	140.8	(70.2-251.9)	Male	5	5.7	88.0	(28.4-205.4)
Female	1	2.6	nc	(nc-nc)	Female	7	4.5	155.3	(62.2-320.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.0	160.3	(69.0-315.9)
Female	34	35.4	95.9	(66.4-134.0)	Female	3	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	13	9.4	137.8	(73.3-235.7)	<u>Ovary</u>				
Female	12	8.3	144.9	(74.8-253.1)	Female	6	3.2	190.2	(69.5-414.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.4	208.9	(67.3-487.4)	Male	1	2.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.8	nc	(nc-nc)	Male	18	33.9	53.1	(31.5-83.9)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	5	5.1	97.9	(31.6-228.6)	Female	0	1.0	nc	(nc-nc)
Female	5	2.6	191.8	(61.8-447.6)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.3	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	8	7.3	110.0	(47.4-216.8)
Male	1	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.3	nc	(nc-nc)	Female	5	8.2	61.3	(19.7-143.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.2	nc	(nc-nc)	Male	109	118.0	92.4	(75.8-111.4)
Female	2	0.9	nc	(nc-nc)	Female	114	111.8	102.0	(84.1-122.5)
<u>Lung and Bronchus</u>									
Male	18	14.9	120.4	(71.3-190.3)					
Female	15	14.2	105.7	(59.1-174.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.8	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	18	12.5	144.5	(85.6-228.4)	Female	2	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	5	4.0	124.8	(40.2-291.3)	<u>Ovary</u>				
Female	3	3.3	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	14.4	55.5	(23.9-109.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.9	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.3	nc	(nc-nc)	Male	35	49.9	70.1	(48.8-97.5)
Female	0	0.4	nc	(nc-nc)	Female	52	41.9	124.0	(92.6-162.6)
<u>Lung and Bronchus</u>									
Male	2	7.0	nc	(nc-nc)					
Female	4	6.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	9.0	156.0	(85.2-261.8)	Male	7	6.7	105.2	(42.1-216.7)
Female	5	3.2	157.8	(50.9-368.3)	Female	6	5.6	107.4	(39.2-233.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
Female	32	43.7	73.3	(50.1-103.4)	Female	3	4.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	5	5.3	95.2	(30.7-222.1)
<u>Colon / Rectum</u>					Female	3	2.1	nc	(nc-nc)
Male	12	11.1	108.1	(55.8-188.8)	<u>Ovary</u>				
Female	8	10.2	78.1	(33.6-154.0)	Female	4	3.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.7	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	31	37.8	82.1	(55.8-116.5)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.3	nc	(nc-nc)
Male	5	6.0	83.9	(27.0-195.8)	Female	1	1.3	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.6	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	10	9.2	108.4	(51.9-199.4)
Male	6	4.0	151.9	(55.5-330.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.8	nc	(nc-nc)	Female	8	9.7	82.2	(35.4-161.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	3.7	214.7	(92.5-423.1)	Male	139	135.7	102.4	(86.1-121.0)
Female	0	1.0	nc	(nc-nc)	Female	126	137.6	91.6	(76.3-109.0)
<u>Lung and Bronchus</u>									
Male	22	17.0	129.6	(81.2-196.2)					
Female	22	17.4	126.5	(79.3-191.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	9.0	89.4	(38.5-176.1)
Female	0	0.1	nc	(nc-nc)	Female	6	7.6	78.9	(28.8-171.7)
<u>Lung and Bronchus</u>									
Male	3	1.3	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.5	108.4	(43.4-223.4)	Male	4	4.7	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	7	4.1	170.3	(68.2-350.8)
Female	36	30.1	119.6	(83.7-165.6)	Female	2	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	5	3.6	138.5	(44.6-323.3)
<u>Colon / Rectum</u>					Female	2	1.4	nc	(nc-nc)
Male	6	7.8	76.8	(28.0-167.1)	<u>Ovary</u>				
Female	3	7.3	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.9	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	18	26.2	68.7	(40.7-108.6)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.6	nc	(nc-nc)
Male	1	4.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.0	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.1	nc	(nc-nc)
Male	4	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.0	nc	(nc-nc)	Female	9	6.7	134.4	(61.3-255.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	2.6	196.0	(63.1-457.3)	Male	86	94.9	90.6	(72.4-111.9)
Female	0	0.7	nc	(nc-nc)	Female	99	95.7	103.4	(84.0-125.9)
<u>Lung and Bronchus</u>									
Male	13	12.1	107.3	(57.1-183.5)					
Female	12	12.4	96.6	(49.9-168.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	13.4	89.2	(46.1-155.9)	Male	13	9.2	141.8	(75.4-242.5)
Female	6	4.7	127.7	(46.6-278.0)	Female	5	7.2	69.8	(22.5-162.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	9	8.1	111.0	(50.7-210.7)
Female	63	55.7	113.2	(87.0-144.8)	Female	4	6.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	12	6.7	178.1	(91.9-311.0)
<u>Colon / Rectum</u>					Female	1	2.7	nc	(nc-nc)
Male	17	15.5	109.6	(63.8-175.5)	<u>Ovary</u>				
Female	16	14.6	109.8	(62.7-178.3)	Female	3	5.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.7	nc	(nc-nc)	Male	6	4.7	128.3	(46.9-279.4)
Female	2	0.9	nc	(nc-nc)	Female	5	4.6	109.9	(35.4-256.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	60	50.4	119.1	(90.9-153.4)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.2	nc	(nc-nc)
Male	8	7.9	101.7	(43.8-200.5)	Female	0	1.8	nc	(nc-nc)
Female	6	4.3	139.3	(50.9-303.2)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.0	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<u>Leukemia</u>					Female	9	10.8	83.3	(38.0-158.2)
Male	6	5.5	108.1	(39.5-235.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.9	154.0	(56.2-335.2)	Female	16	12.5	128.2	(73.2-208.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.9	nc	(nc-nc)	Male	221	186.8	118.3	(103.2-135.0)
Female	1	1.5	nc	(nc-nc)	Female	190	183.4	103.6	(89.4-119.5)
<u>Lung and Bronchus</u>									
Male	31	24.6	126.0	(85.6-178.8)					
Female	24	25.0	96.2	(61.6-143.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	27.8	111.5	(75.7-158.2)	Male	22	18.1	121.8	(76.3-184.4)
Female	8	10.4	76.9	(33.1-151.5)	Female	27	14.8	182.5	(120.2-265.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.2	135.0	(54.1-278.2)	Male	4	5.3	nc	(nc-nc)
Female	5	4.5	110.4	(35.6-257.7)	Female	3	4.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	11	16.0	68.9	(34.4-123.3)
Female	124	112.9	109.8	(91.3-130.9)	Female	23	13.9	165.5	(104.9-248.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.0	nc	(nc-nc)	Male	12	12.7	94.1	(48.6-164.5)
<u>Colon / Rectum</u>					Female	3	5.8	nc	(nc-nc)
Male	37	30.7	120.4	(84.7-165.9)	<u>Ovary</u>				
Female	36	31.9	112.9	(79.0-156.3)	Female	6	10.3	58.2	(21.3-126.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.4	107.8	(46.4-212.5)	Male	7	9.4	74.3	(29.7-153.0)
Female	2	2.0	nc	(nc-nc)	Female	10	10.2	98.3	(47.1-180.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.2	nc	(nc-nc)	Male	82	98.6	83.2	(66.2-103.2)
Female	0	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.5	nc	(nc-nc)
Male	8	15.1	53.1	(22.9-104.7)	Female	2	4.0	nc	(nc-nc)
Female	8	9.0	89.1	(38.4-175.6)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.6	137.3	(44.2-320.4)
Male	5	4.1	121.8	(39.2-284.2)	<u>Thyroid</u>				
Female	2	1.4	nc	(nc-nc)	Male	6	6.9	86.5	(31.6-188.2)
<u>Leukemia</u>					Female	25	21.0	118.9	(76.9-175.5)
Male	11	11.0	100.0	(49.8-178.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	8.3	84.4	(33.8-173.9)	Female	16	25.6	62.5	(35.7-101.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	9.4	53.0	(17.1-123.8)	Male	335	369.4	90.7	(81.2-100.9)
Female	5	3.1	159.8	(51.5-373.0)	Female	396	383.5	103.3	(93.3-113.9)
<u>Lung and Bronchus</u>									
Male	42	50.1	83.8	(60.4-113.3)					
Female	53	53.6	98.9	(74.1-129.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.0	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	8	7.6	105.2	(45.3-207.2)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	0	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	6	1.8	333.5	(121.8-725.9)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	8.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	2	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.5	nc	(nc-nc)	Female	5	1.8	276.1	(89.0-644.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.8	nc	(nc-nc)	Male	26	28.6	91.0	(59.5-133.4)
Female	0	0.2	nc	(nc-nc)	Female	32	24.4	131.3	(89.8-185.4)
<u>Lung and Bronchus</u>									
Male	5	3.8	132.5	(42.7-309.2)					
Female	5	3.2	154.3	(49.7-360.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;